Molecular imaging developer Positron announced it is developing indium oxine, a radiopharmaceutical used for radiolabeling blood elements.
Indium oxine is the first new product in development at Positron's research, development, and manufacturing facility in Crown Point, IN. The operation received U.S. Nuclear Regulatory Commission (NRC) approval last month to handle radioactive materials.
Positron initially intends to produce a radiochemical-grade indium oxine product that will be commercially available in the second quarter, with radiopharmaceutical-grade availability upon clearance from the U.S. Food and Drug Administration (FDA). The company estimates the market for indium oxine to be worth about $20 million annually.
